#SLAS2024

[mysticalpeacenut]

Depixus Wins SLAS2024 Ignite Award for MAGNA Technology - Depixus

[mysticalpeacenut]

Depixus Wins SLAS2024 Ignite Award for MAGNA Technology - Depixus

Paris, France – Interactomics pioneer Depixus has won the prestigious Society for Laboratory Automation and Screening (SLAS) Ignite Award at the society’s annual International Conference and Exhibition in Boston, MA, for their novel MAGNA™ technology. The award coincides with the first showing of Depixus’ ground-breaking MAGNA One™ instrument at the conference.

The Ignite Award recognizes exciting companies providing game-changing technologies for the life sciences. Judged by a panel of experts, participants were scored on excellence in innovation, marketing presence and opportunity, messaging, impact, funding, and balanced leadership.

Depixus was one of just 16 companies selected to participate in the SLAS2024 Innovation AveNEW program – a specially designated area for start-ups and emerging companies within the conference – of which the top eight were shortlisted as finalists for the Ignite Award.

Based on magnetic force spectroscopy, MAGNA One enables  scalable analysis of dynamic biomolecular interactions. This technology is the first to offer direct, simultaneous, and real-time measurements from thousands of individual molecules.

It is particularly useful for exploring challenging targets such as RNA and protein-protein interactions, providing invaluable insights into disease mechanisms and accelerating the development of novel therapeutics.

Depixus CEO Gordon Hamilton says, “We’re thrilled to have won this year’s Ignite Award against such stiff competition and congratulate all the other finalists. This recognition is a great way to celebrate the company we are building, our innovative technology, and its potential to impact the understanding and treatment of diseases where new approaches are urgently needed.”Depixus Wins SLAS2024 Ignite Award for MAGNA Technology, Depixus Chief Commercial Officer Steve Klose added, “The timing of this award aligns perfectly with the launch of our technology access program and commercial rollout of MAGNA One. It’s been an honor to unveil our new instrument to the world at SLAS2024, and we’re excited to see how the scientific community puts it to work to transform research.”

[mysticalpeacenut]

Depixus Wins SLAS2024 Ignite Award for MAGNA Technology

Depixus introduces MAGNA™, a groundbreaking technology that utilizes magnetic force spectroscopy to examine biomolecular interactions at the single-molecule level, unlocking a new era in disease research and therapeutic development. MAGNA™ recently won the prestigious SLAS2024 Ignite Award, a testament to its revolutionary potential.

[mysticalpeacenut]

Depixus: Decoding Disease Mechanisms with Magnetic Force Spectroscopy

In the ever-evolving field of healthcare, new discoveries are constantly being made, paving the way for advancements in disease diagnosis and treatment. Depixus, a pioneering company, is at the forefront of this progress, introducing a groundbreaking technology called MAGNA™.

What is MAGNA™?

MAGNA™ stands for Magnetic Atomics for Granular Nanoparticle Assays. This innovative technology leverages the power of magnetic force spectroscopy to unveil the intricacies of biomolecular interactions. By meticulously measuring the forces between biomolecules, MAGNA™ provides unparalleled insights into the mechanisms underlying various diseases.

The Potential of MAGNA™

The potential applications of MAGNA™ are extensive and hold immense promise for the future of healthcare. Here are a few noteworthy examples:

Decoding Disease Mechanisms: MAGNA™’s ability to elucidate biomolecular interactions can shed light on the complex pathways involved in disease development. This deeper understanding can pave the way for the development of more targeted and effective therapies.

Drug Discovery and Development: By enabling researchers to precisely map the interactions between drugs and their targets, MAGNA™ can accelerate the drug discovery and development process. This can lead to the creation of more potent and specific drugs with fewer side effects.

Personalized Medicine: MAGNA™’s ability to analyze individual biomolecular profiles has the potential to revolutionize personalized medicine. By tailoring treatments to each patient’s unique molecular makeup, healthcare professionals can provide more effective and individualized care.

The Depixus Mission

Depixus is committed to harnessing the transformative potential of MAGNA™ to revolutionize healthcare. By providing researchers with a powerful tool to unlock the secrets of biomolecular interactions, Depixus aims to contribute significantly to the development of life-saving therapies and improved patient outcomes.

If you are interested in learning more about MAGNA™ technology and its potential applications, visit the Depixus website or contact them directly. Together, we can explore the exciting possibilities that MAGNA™ holds for the future of healthcare.

[mysticalpeacenut]

Depixus Wins Prestigious SLAS 2024 Innovation AveNEW Award

Explore Depixus' groundbreaking success as it secures the coveted SLAS 2024 Innovation AveNEW Award. Dive into advancements shaping the future of life sciences technology. Stay ahead with Depixus' innovative solutions and expertise.

[mysticalpeacenut]

Depixus: Decoding Disease Mechanisms with Magnetic Force Spectroscopy